The DOI matches its Crossref record; 78 of the 79 references it cites were found in a registry or an index.
Gut microbiota modulate dendritic cell antigen presentation and radiotherapy-induced antitumor immune response
Open accessAbstract
Alterations in gut microbiota impact the pathophysiology of several diseases, including cancer. Radiotherapy (RT), an established curative and palliative cancer treatment, exerts potent immune modulatory effects, inducing tumor-associated antigen (TAA) cross-priming with antitumor CD8+ T cell elicitation and abscopal effects. We tested whether the gut microbiota modulates antitumor immune response following RT distal to the gut. Vancomycin, an antibiotic that acts mainly on gram-positive bacteria and is restricted to the gut, potentiated the RT-induced antitumor immune response and tumor growth inhibition. This synergy was dependent on TAA cross presentation to cytolytic CD8+ T cells and on IFN-γ. Notably, butyrate, a metabolite produced by the vancomycin-depleted gut bacteria, abrogated the vancomycin effect. In conclusion, depletion of vancomycin-sensitive bacteria enhances the antitumor activity of RT, which has important clinical ramifications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In mouse models, certain gut commensals mediate efficacy of anticancer therapies, including chemotherapy, radiotherapy, and immunotherapies such as adoptive T cell transfer, intratumoral CpG-oligonucleotides, and ICIs.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“High serum levels of butyrate and propionate have been associated with resistance to anti-CTLA-4 antibodies and radiotherapy and increased Treg cell numbers in patients with melanoma.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“whereas some studies found that gut commensals were able to impact tumor growth independently [33, 138].”
From Gut microbiota-mediated immunomodulation in tumor (2021) · cites this paper as [138]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
QIIME allows analysis of high-throughput community sequencing data
Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., Fierer, N., Peña, A. G., Goodrich, J. K., Gordon, J. I., et al. (2010) · Nature Methods · doi:10.1038/nmeth.f.303 · Cited by 34,887
Self-citationSearch and clustering orders of magnitude faster than BLAST
Edgar, R. C. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq461 · Cited by 20,826
FastTree 2 – Approximately Maximum-Likelihood Trees for Large Alignments
Price, M. N., Dehal, P. S., & Arkin, A. P. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009490 · Cited by 14,894 · cited 3×
“FastTree 2--approximately maximum-likelihood trees for large alignments.”
MethodUniFrac: a New Phylogenetic Method for Comparing Microbial Communities
Lozupone, C., & Knight, R. (2005) · Applied and Environmental Microbiology · doi:10.1128/aem.71.12.8228-8235.2005 · Cited by 8,227 · cited 1×
“(77) were computed between each pair of samples using QIIME.”
MethodGut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells
Furusawa, Y., Obata, Y., Fukuda, S., Endo, T. A., Nakato, G., Takahashi, D., Nakanishi, Y., Uetake, C., Kato, K., Kato, T., et al. (2013) · Nature · doi:10.1038/nature12721 · Cited by 5,549 · cited 1×
“SCFAs produced by colonic Clostridia were also shown to induce the differentiation of colonic Treg cells in mice (68).”
BackgroundRole of the microbiota in immunity and inflammation.
Belkaid, Y., & Hand, T. W. (2014) · Cell · doi:10.1016/j.cell.2014.03.011 · Cited by 5,385
den Besten, G., van Eunen, K., Groen, A. K., Venema, K., Reijngoud, D.-J., & Bakker, B. M. (2013) · Journal of Lipid Research · doi:10.1194/jlr.r036012 · Cited by 5,048
Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation
Arpaia, N., Campbell, C., Fan, X., Dikiy, S., van der Veeken, J., deRoos, P., Liu, H., Cross, J. R., Pfeffer, K., Coffer, P. J., et al. (2013) · Nature · doi:10.1038/nature12726 · Cited by 4,838 · cited 1×
“Although DCs can also modulate T cells in a butyrate-dependent manner (67), to our knowledge, the direct impact on antigen presentation in the context of RT has not been investigated.”
BackgroundGut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Research works printed but not linked: 1
- 10.1038/nature14292 · DOI · Paper page
Cited by
Microbiota in health and diseases
Hou, K., Wu, Z.-X., Chen, X.-Y., Wang, J.-Q., Zhang, D., Xiao, C., Zhu, D., Koya, J. B., Wei, L., Li, J., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00974-4 · Cited by 3,171
“In a study of melanoma and lung cancer models, vancomycin can enhance the anti-tumor response induced by radiotherapy in mice by increasing CD8+ T cell infiltration and IFN-γ expression.(358) Many studies have shown that antibiotics can prevent cancer development or attenuate tumor proliferation.”
BackgroundThe microbiome and human cancer
Sepich-Poore, G. D., Zitvogel, L., Straussman, R., Hasty, J., Wargo, J. A., & Knight, R. (2021) · Science · doi:10.1126/science.abc4552 · Cited by 1,332
“Radiotherapy of tumor lesions was more effective when vancomycin eliminated Clostridiales-derived immunosuppressivemetabolites (butyrate and propionate) putatively by increasing DC antigen presentation and concomitant CD8 T cell priming (72); conversely, gut microbial–derived propionate and tryptophan pathway metaboli…”
BackgroundCullin, N., Azevedo Antunes, C., Straussman, R., Stein-Thoeringer, C. K., & Elinav, E. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.08.006 · Cited by 578
“Beyond those associations, mouse studies demonstrated that oral vancomycin-induced depletion of Gram-positive gut commensals was correlated with enhanced radiotherapy effectiveness in melanoma, lung, and cervical cancer models, potentially mediated through IFNg and CD8 T cell– dependent mechanisms (Uribe-Herranz et al…”
BackgroundBehary, J., Amorim, N., Jiang, X.-T., Raposo, A., Gong, L., McGovern, E., Ibrahim, R., Chu, F., Stephens, C., Jebeili, H., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20422-7 · Cited by 470
The role of gut microbiota in cancer treatment: friend or foe?
Cheng, W. Y., Wu, C.-Y., & Yu, J. (2020) · Gut · doi:10.1136/gutjnl-2020-321153 · Cited by 384
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
Smith, M., Dai, A., Ghilardi, G., Amelsberg, K. V., Devlin, S. M., Pajarillo, R., Slingerland, J. B., Beghi, S., Herrera, P. S., Giardina, P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01702-9 · Cited by 349
Self-citationTargeting the gut microbiota for cancer therapy
Fernandes, M. R., Aggarwal, P., Costa, R. G. F., Cole, A. M., & Trinchieri, G. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00513-x · Cited by 290
Immunomodulation by radiotherapy in tumour control and normal tissue toxicity
Cytlak, U. M., Dyer, D. P., Honeychurch, J., Williams, K. J., Travis, M. A., & Illidge, T. M. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00568-1 · Cited by 258
A Review of Gut Microbiota‐Derived Metabolites in Tumor Progression and Cancer Therapy
Yang, Q., Wang, B., Zheng, Q., Li, H., Meng, X., Zhou, F., & Zhang, L. (2023) · Advanced Science · doi:10.1002/advs.202207366 · Cited by 240
Yi, Y., Shen, L., Shi, W., Xia, F., Zhang, H., Wang, Y., Zhang, J., Wang, Y., Sun, X., Zhang, Z., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3445 · Cited by 200
“Furthermore, butyrate produced by vancomycin-depleted gut microbes abrogated this synergistic effect by impacting dendritic cell functions (54).”
BackgroundRadiotherapy and the gut microbiome: facts and fiction
Liu, J., Liu, C., & Yue, J. (2021) · Radiation Oncology · doi:10.1186/s13014-020-01735-9 · Cited by 183
“This synergy depended on cross-presentation of tumorspecific antigens to cytolytic CD8 + T cells and on interferon-γ [34].”
BackgroundNew Insights Into the Cancer–Microbiome–Immune Axis: Decrypting a Decade of Discoveries
Jain, T., Sharma, P., Are, A. C., Vickers, S. M., & Dudeja, V. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.622064 · Cited by 183
“As already described, butyrate secreted by the gut microbes has also been shown to inhibit DC mediated antigen presentation in models of radiation induced tumor necrosis leading to inhibition of crosspriming of tumor specific CD8 T cells (120).”
BackgroundMetabolic programming in dendritic cells tailors immune responses and homeostasis
Møller, S. H., Wang, L., & Ho, P.-C. (2022) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00753-1 · Cited by 169
Microbiota-Centered Interventions: The Next Breakthrough in Immuno-Oncology?
Derosa, L., Routy, B., Desilets, A., Daillère, R., Terrisse, S., Kroemer, G., & Zitvogel, L. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0236 · Cited by 170
Gut Microbiota in Colorectal Cancer: Biological Role and Therapeutic Opportunities
Pandey, H., Tang, D. W. T., Wong, S. H., & Lal, D. (2023) · Cancers · doi:10.3390/cancers15030866 · Cited by 159
Gut Microbiota-Derived Short-Chain Fatty Acids: Impact on Cancer Treatment Response and Toxicities
Al-Qadami, G. H., Secombe, K. R., Subramaniam, C. B., Wardill, H. R., & Bowen, J. M. (2022) · Microorganisms · doi:10.3390/microorganisms10102048 · Cited by 162
“They also reported that butyrate reduced antigenpresenting cell (APC) activation and function and hence impaired the radiation-induced anti-tumor response [57] (Figure 2).”
BackgroundRadiotherapy and immunotherapy: open questions and future strategies
Pointer, K. B., Pitroda, S. P., & Weichselbaum, R. R. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.10.003 · Cited by 173
Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy
Thomas, A. M., Fidelle, M., Routy, B., Kroemer, G., Wargo, J. A., Segata, N., & Zitvogel, L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00785-8 · Cited by 141
Role of the microbiota in response to and recovery from cancer therapy
Blake, S. J., Wolf, Y., Boursi, B., & Lynn, D. J. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00951-0 · Cited by 158
“Furthermore, butyrate increased radiotherapy-induced abscopal effects in mice by enhancing cross-presentation by dendritic cells, which promotes CD8 + T cell-mediated clearance of tumours that were not directly irradiated 40 .”
Li, Z., Zhang, Y., Hong, W., Wang, B., Chen, Y., Yang, P., Zhou, J., Fan, J., Zeng, Z., & Du, S. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2119055 · Cited by 142
“Gut microbiome dysbiosis significantly suppressed the proportion and maturation rates of DCs, consistent with the findings of previous studies (Figure 3h,i).(19) To determine whether functional differences in DCs could explain the differences in T cell priming observed in vivo, we purified a CD11c population from TDLN…”
ResultWang, L., Lynch, C. M., Pitroda, S. P., Piffkó, A., Yang, K., Huser, A. K., Liang, H. L., & Weichselbaum, R. R. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20232101 · Cited by 155
Ouyang, J., Lin, J., Isnard, S., Fombuena, B., Peng, X., Marette, A., Routy, B., Messaoudene, M., Chen, Y., & Routy, J.-P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00645 · Cited by 124
“muciniphila which was associated with tumor growth inhibition in mouse models (86).”
BackgroundYang, K., Hou, Y., Zhang, Y., Liang, H. L., Sharma, A., Zheng, W., Wang, L., Torres, R., Tatebe, K., Chmura, S. J., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20201915 · Cited by 130
“Recently, the Facciabene group also found that vancomycin administration decreased the systemic concentration of butyrate and modulated the IR-induced antitumor response on DCs in the tumor-draining LN in B16 melanoma and TC-1 lung/cervical tumor models (Uribe-Herranz et al., 2020).”
BackgroundGut microbiota-mediated immunomodulation in tumor
Liu, X., Chen, Y., Zhang, S., & Dong, L. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01983-x · Cited by 112
The Potential of the Gut Microbiome to Reshape the Cancer Therapy Paradigm: A Review
Liu, L., & Shah, K. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.0494 · Cited by 121
Sun, J., Chen, F., & Wu, G. (2023) · The ISME Journal · doi:10.1038/s41396-023-01483-0 · Cited by 126
“activate dc to reverse immune tolerance induced by immature DCs [43].”
BackgroundInfluentialCustomized materials-assisted microorganisms in tumor therapeutics
Chen, Q., Qiao, J., Liu, X., Zhang, C., & Zhang, X. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01571g · Cited by 110
Zou, Y., Wang, S., Zhang, H., Gu, Y., Chen, H., Huang, Z., Yang, F., Li, W., Chen, C., Men, L., et al. (2023) · Medicinal Research Reviews · doi:10.1002/med.21989 · Cited by 108
“64 To cope with the RT ‐ induced cognitive dysfunction, gut microbiota regulates the central nervous system.”
BackgroundZhou, H., Tu, C., Yang, P., Li, J., Kepp, O., Li, H., Zhang, L., Zhang, L., Zhao, Y., Zhang, T., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2057892 · Cited by 96
“approach, and a large body of preclinical data suggests that radiotherapy is enhancing the activity of immunotherapy.(32,33)”
BackgroundTumor microenvironment as a complex milieu driving cancer progression: a mini review
Li, Z., Li, J., Bai, X., Huang, X., & Wang, Q. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03697-w · Cited by 104
Melanoma and microbiota: Current understanding and future directions
Routy, B., Jackson, T., Mählmann, L., Baumgartner, C. K., Blaser, M., Byrd, A., Corvaia, N., Couts, K., Davar, D., Derosa, L., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.003 · Cited by 89
The human microbiome and cancer: a diagnostic and therapeutic perspective
Kandalai, S., Li, H., Zhang, N., Peng, H., & Zheng, Q. (2023) · Cancer Biology & Therapy · doi:10.1080/15384047.2023.2240084 · Cited by 101
“Further, reintroducing the short-chain fatty acid (SCFA) metabolite sodium butyrate, normally produced by Gram-positive bacteria, nullified the improvement in radiotherapy seen with antibiotic treatment.(102) Complete depletion of gut bacteria has also been shown to reduce the efficacy of radiation treatment in breast…”
BackgroundLee, K. A., Shaw, H. M., Bataille, V. A., Nathan, P., & Spector, T. D. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.07.026 · Cited by 94
Gut Microbiota Influence in Hematological Malignancies: From Genesis to Cure
Uribe‐Herranz, M., Klein-González, N., Rodríguez‐Lobato, L. G., Juan, M., & de Larrea, C. F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031026 · Cited by 88
“fragilis can promote the increase in systemic T helper cell type 1 (Th1) CD4+ T cells [39]; and SCFAs can regulate extrathymic/peripheral T regs [32] and DC cytokine production and function [34,35] (Figure 1).”
BackgroundSelf-citationKhan, N., Lindner, S., Gomes, A. L. C., Devlin, S. M., Shah, G. L., Sung, A. D., Sauter, C. S., Landau, H. J., Dahi, P. B., Perales, M., et al. (2020) · Blood · doi:10.1182/blood.2020006923 · Cited by 85
Interaction between intestinal microbiota and tumour immunity in the tumour microenvironment
Yang, X., Guo, Y., Chen, C., Shao, B., Zhao, L., Zhou, Q., Liu, J., Wang, G., Yuan, W., & Sun, Z. (2021) · Immunology · doi:10.1111/imm.13397 · Cited by 86
“This is accompanied by the remodelling of the tumour microenvironment and the increase of antigen presentation and cytotoxic T- cell infiltration in the tumour [98].”
BackgroundGut microbiome in gastrointestinal cancer: a friend or foe?
Liu, Y., Baba, Y., Ishimoto, T., Gu, X. J., Zhang, J., Nomoto, D., Okadome, K., Baba, H., & Qiu, P. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.69331 · Cited by 85
“Radiotherapy can promote tumor cytotoxicity and the systemic immune response regulated by the immune system [120].”
BackgroundTonneau, M., Elkrief, A., Pasquier, D., del Socorro, T. P., Chamaillard, M., Bahig, H., & Routy, B. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.10.033 · Cited by 78
Hu, B., Xiao, X., Chen, P., Qian, J., Yuan, G., Ye, Y., Zeng, L., Zhong, S., Wang, X., Qin, X., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121811 · Cited by 73
The Role of the Microbiome in the Etiopathogenesis of Colon Cancer
Tekle, G. E., Andreeva, N., & Garrett, W. S. (2024) · Annual Review of Physiology · doi:10.1146/annurev-physiol-042022-025619 · Cited by 85
Gut microbiota as a new target for anticancer therapy: from mechanism to means of regulation
Sun, J., Song, S., Liu, J., Chen, F., Li, X., & Wu, G. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00678-x · Cited by 89
“Onestudyfound that radiotherapy combined with vancomycin, an antibiotic that acts primarily on gram-positive, signi fi cantly increased survival in mice with lung cancercomparedtoradiotherapyalone,andtheprocesswasassociatedwith anincreaseinthenumberoftumorscell-lysingCD8 + T cells 102 (Fig.”
Beyond the Gut: The intratumoral microbiome's influence on tumorigenesis and treatment response
Zhang, H., Fu, L., Leiliang, X., Qu, C., Wu, W., Wen, R., Huang, N., He, Q., Cheng, Q., Liu, G., et al. (2024) · 癌症:英文版 · doi:10.1002/cac2.12597 · Cited by 78
“Vancomycin, an antibiotic limited to the gut and mostly targets gram-positive bacteria, was discovered by Uribe-Herranz et al. [222] in 2019 to enhance the RT-induced antitumor immune response and tumor growth suppression.”
BackgroundChen, J., Levy, A., Tian, A.-L., Huang, X., Cai, G., Fidelle, M., Rauber, C., Ly, P., Pizzato, E., Sitterle, L., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.02.010 · Cited by 67
Uribe‐Herranz, M., Beghi, S., Ruella, M., Parvathaneni, K., Salaris, S., Κωστόπουλος, Ν., George, S. S., Pierini, S., Krimitza, E., Costabile, F., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.01.012 · Cited by 71
Self-citationZhu, R., Lang, T., Yan, W., Zhu, X. G., Huang, X. Y., Yin, Q., & Li, Y. (2021) · Advanced Science · doi:10.1002/advs.202003542 · Cited by 67
Immunomodulation of dendritic cells byLactobacillus reuterisurface components and metabolites
Engevik, M. A., Ruan, W. H., Esparza, M., Fultz, R., Shi, Z., Engevik, K. A., Engevik, A. C., Ihekweazu, F. D., Visuthranukul, C., Venable, S. F., et al. (2021) · Physiological Reports · doi:10.14814/phy2.14719 · Cited by 73
Huang, J., Chen, P., Xiang, Y., Liang, Q., Wu, T., Liu, J., Zeng, Y., Zeng, H., Liang, X., & Zhou, C. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108717 · Cited by 76
Gut Microbiome Modulates Response to Cancer Immunotherapy
Khan, M. A. W., Ologun, G. O., Arora, R., McQuade, J. L., & Wargo, J. A. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06111-x · Cited by 75
Zheng, H., Guo, B., Qiu, X., Xia, Y., Qu, Y., Cheng, L., Meng, F., & Zhong, Z. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.02.029 · Cited by 67
Effects of laboratory domestication on the rodent gut microbiome
Bowerman, K. L., Knowles, S. C. L., Bradley, J. E., Baltrūnaitė, L., Lynch, M. D. J., Jones, K. M., & Hugenholtz, P. (2021) · ISME Communications · doi:10.1038/s43705-021-00053-9 · Cited by 65
Radiotherapy-Induced Digestive Injury: Diagnosis, Treatment and Mechanisms
Chen, G., Han, Y., Zhang, H., Tu, W., & Zhang, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.757973 · Cited by 68
Lu, L., Li, F., Gao, Y., Kang, S., Li, J., & Guo, J. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00873-0 · Cited by 63
“Similarly, according to Uribe-Herranz and colleagues [47], butyrate affected the expression of co-stimulatory molecules and antigen presentation by DCs but did not directly affect T cell IFN-γ production.”
BackgroundResultInfluentialAge‐mediated gut microbiota dysbiosis promotes the loss of dendritic cells tolerance
Bashir, H., Singh, S., Singh, R. P., Agrewala, J. N., & Kumar, R. (2023) · Aging Cell · doi:10.1111/acel.13838 · Cited by 55
Li, N., Han, X., Ruan, M., Huang, F., Liu, Y., Xu, T., Wang, H., Wu, H., Shi, S., Wang, Y., et al. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2402547 · Cited by 59
“58 In addition, butyrate can also inhibit the antigen presentation ability of DCs. 59 We found that inulin significantly increased butyrate concentration in EAE mice while decreasing the activation of Th17 cells and DCs.”
BackgroundFilippou, C., Themistocleous, S., Marangos, G., Panayiotou, Y., Fyrilla, M., Kousparou, C. A., Pana, Z. D., Tsioutis, C., Johnson, E. O., & Yiallouris, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021110 · Cited by 51
“However, reintroducing the metabolite sodium butyrate, produced by these bacteria, eliminated this benefit [50].”
BackgroundFunctions of Dendritic Cells and Its Association with Intestinal Diseases
Yang, Z., Wang, B., Wang, T., Wang, F., Guo, Y., Hua, R., Shang, H., Lü, X., & Xu, J. (2021) · Cells · doi:10.3390/cells10030583 · Cited by 51
“In addition, during intestinal tumor therapy, DCs from the combination treatment group of radiotherapy and vancomycin significantly increased when compared with radiotherapy, which indicates the potential relationship between intestinal bacterial and DCs [93].”
BackgroundMicroglia and gut microbiota: A double-edged sword in Alzheimer's disease
Bano, N., Khan, S., Ahamad, S., Kanshana, J. S., Dar, N. J., Khan, S. J., Nazir, A., & Bhat, S. A. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102515 · Cited by 52
The impact of the gut microbiome on tumor immunotherapy: from mechanism to application strategies
Guo, C., Kong, L., Xiao, L., Liu, K., Cui, H., Xin, Q., Gu, X., Jiang, C., & Wu, J. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01135-y · Cited by 48
“Moreover, metabolites produced by bacteria, typically SCFAs [74] or tryptophan derivatives [79], can also induce T-cell-or DC cell-dependent adaptive immune responses.”
BackgroundInfluentialMicrobiota in cancer: molecular mechanisms and therapeutic interventions
Chen, Z., Guan, D., Wang, Z., Li, X., Dong, S., Huang, J., & Zhou, W. (2023) · MedComm · doi:10.1002/mco2.417 · Cited by 50
Cui, C., Hong, H., Shi, Y., Zhou, Y., Qiao, C.-M., Zhao, W.-J., Zhao, L.-P., Wu, J., Quan, W., Niu, G.-Y., et al. (2023) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-021-10047-y · Cited by 45
Exploiting dietary fibre and the gut microbiota in pelvic radiotherapy patients
Eaton, S. E., Kaczmarek, J., Mahmood, D., McDiarmid, A. M., Norarfan, A. N., Scott, E. G., Then, C. K., Tsui, H. Y., & Kiltie, A. E. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01980-7 · Cited by 45
“Vancomycin, an antibiotic that kills Grampositive bacteria in the gut, successfully enhanced radiotherapy efficacy via increasing dendritic cell antigen presentation [14, 15].”
BackgroundGut Microbiota and Tumor Immune Escape: A New Perspective for Improving Tumor Immunotherapy
He, Y., Huang, J., Li, Q., Xia, W., Zhang, C., Liu, Z., Xiao, J., Yi, Z., Deng, H., Xiao, Z., et al. (2022) · Cancers · doi:10.3390/cancers14215317 · Cited by 49
Gut microbiota in brain tumors: An emerging crucial player
Lin, B. C., Ye, Z., Ye, Z., Wang, M., Cao, Z., Gao, R., & Zhang, Y. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14081 · Cited by 47
Butyrate Prevents the Pathogenic Anemia‐Inflammation Circuit by Facilitating Macrophage Iron Export
Xiao, P., Cai, X., Zhang, Z., Guo, K., Ke, Y., Hu, Z., Song, Z., Zhao, Y., Yao, L., Shen, M., et al. (2024) · Advanced Science · doi:10.1002/advs.202306571 · Cited by 51
Gut microbial metabolites in cancer immunomodulation
Liu, H., Xiong, X., Zhu, W., Wang, S., Huang, W.-C., Zhu, G., Xu, H., & Yang, L. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02521-5 · Cited by 62
“Butyrate can not only improve and modulate the function and differentiation of NK cells, B cells, macrophages and DCs through a variety of ways [94–96], but also augment chemotherapy efficacy and induce ferrop-tosis, thereby promoting long-term antitumor memory [14, 97–102].”
Kubeček, O., Paterová, P., & Novosadová, M. (2021) · Life · doi:10.3390/life11121387 · Cited by 60
Then, C. K., Paillas, S., Moomin, A., Misheva, M., Moir, R., Hay, S. M., Bremner, D. M., Roberts, K. S., Smith, E. E., Heidari, Z., et al. (2024) · Microbiome · doi:10.1186/s40168-024-01804-1 · Cited by 52
“The main alternative strategy in vivo has used antibiotics in studying the role of the gut microbiota in relation to radiotherapy efficacy [11, 24].”
BackgroundCharged Particle and Conventional Radiotherapy: Current Implications as Partner for Immunotherapy
Marcus, D., Lieverse, R. I. Y., Klein, C., Abdollahi, A., Lambin, P., Dubois, L. J., & Yaromina, A. (2021) · Cancers · doi:10.3390/cancers13061468 · Cited by 44
“Apart from the IO mentioned here, the field is in constant development; for example, IO of viral particles and bacterial spores is ongoing [250,251].”
BackgroundFacts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy
Davar, D., & Zarour, H. M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1129 · Cited by 40
“The gut microbiome also mediates the effects of hypofractionated radiotherapy on irradiated and nonradiated tumors in an IFNg and cytotoxic T-cell–dependent manner in melanoma and human papillomavirus (HPV)-driven cancer models (18).”
BackgroundDietary fiber ameliorates sleep disturbance connected to the gut–brain axis
Tang, M., Song, X., Zhong, W., Xie, Y., Liu, Y., & Zhang, X. (2022) · Food & Function · doi:10.1039/d2fo01178f · Cited by 45
New Insights into the Relationship between Gut Microbiota and Radiotherapy for Cancer
Li, Z., Ke, X., Dan, Z., Wang, Z., Fang, F., & Li, B. (2022) · Nutrients · doi:10.3390/nu15010048 · Cited by 40
Microbial metabolites are involved in tumorigenesis and development by regulating immune responses
Liu, J., Tian, R., Sun, C., Guo, Y., Dong, L., Li, Y., & Song, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1290414 · Cited by 41
“Additionally, the role of SCFAs in lung cancer (31), PAs in brain tumors and neuroblastoma (32, 33), SCFAs, MTCs and secondary bile acids in digestive system tumors (21, 34 – 36), and SCFAs, MTCs and PAs in gynecological tumors and melanoma (31, 34, 37 – 42) have also been con fi rmed.”
BackgroundChen, C., Su, Q., Zi, M., Hua, X., & Zhang, Z. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00818-3 · Cited by 51
“Research has shown that oral vancomycin enhances both the direct and abscopal antitumor effects of hypofractionated RT in preclinical models of melanoma and lung/cervical tumors 201 .”
Diet-microbiome interactions in cancer
Abdeen, S. K., Mastandrea, I., Stinchcombe, N., Puschhof, J., & Elinav, E. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.013 · Cited by 36
Computational methods and challenges in analyzing intratumoral microbiome data
Wang, Q., Liu, Z., Ma, A., Li, Z., Liu, B., & Ma, Q. (2023) · Trends in Microbiology · doi:10.1016/j.tim.2023.01.011 · Cited by 37
“They exhibit broad effects on primary lymphoid organs [5,6], the TME [2,7,8], adaptive immune responses [9,10], and in fl ammatory responses in the intestines and other organs [11].”
BackgroundTurchan, W. T., Pitroda, S. P., & Weichselbaum, R. R. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0145 · Cited by 37
Wang, M., Zhang, L., Chang, W., & Zhang, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1096551 · Cited by 45
Pierini, S., Mishra, A., Perales-Linares, R. F., Uribe‐Herranz, M., Beghi, S., Giglio, A., Pustylnikov, S., Costabile, F., Rafail, S., Amici, A. R. D., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001636 · Cited by 39
Self-citationChen, Y., Xiao, N., Chen, Y., Chen, X., Zhong, C., Cheng, Y., Du, B., & Li, P. (2021) · Food Research International · doi:10.1016/j.foodres.2021.110808 · Cited by 39
The role of the symbiotic microecosystem in cancer: gut microbiota, metabolome, and host immunome
Xue, X., Li, R., Chen, Z., Li, G., Liu, B., Guo, S., Yue, Q., Yang, S., Xie, L., Zhang, Y., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1235827 · Cited by 39
Montero, B. K., Wasimuddin, Schwensow, N., Gillingham, M. A. F., Ratovonamana, Y. R., Rakotondranary, S. J., Corman, V. M., Drosten, C., Ganzhorn, J. U., & Sommer, S. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009675 · Cited by 38
“Evidence of compositional differences in the microbiome associated to primed CD8 T-cells by MHC class I molecules is scarce, although the MHC class I pathway synergizes with specific bacterial taxa to mediate parasite resistance [2, 25] and tumor development [26].”
BackgroundHuang, X., Chen, C., Xie, W., Zhou, C., Tian, X. W., Zhang, Z., Wang, Q., Chang, H., Xiao, W., Zhang, R., et al. (2023) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2023.06.2515 · Cited by 36
Poonacha, K. N. T., Villa, T. G., & Notario, V. (2022) · Antibiotics · doi:10.3390/antibiotics11030331 · Cited by 39
“Yet, these microbiota alterations may be important determinants of RT anti-tumor effectiveness [28,29].”
BackgroundBurcher, K. M., Burcher, J. T., Inscore, L., Bloomer, C. H., Furdui, C. M., & Porosnicu, M. (2022) · Cancers · doi:10.3390/cancers14174116 · Cited by 37
Wang, Y., Wang, L., Li, T., Ouyang, M., Xiong, H., & Zhou, D. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.11.028 · Cited by 34
Therapeutic Potential of Chlorogenic Acid in Chemoresistance and Chemoprotection in Cancer Treatment
Cortez, N., Villegas, C., Burgos, V., Ortíz, L., Cabrera‐Pardo, J. R., & Paz, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105189 · Cited by 38
Zhuang, H. (2020) · 癌症:英文版 · doi:10.1002/cac2.12111 · Cited by 42
Microbiota as the unifying factor behind the hallmarks of cancer
Benešová, I., Křížová, Ľ., & Kverka, M. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05244-6 · Cited by 35
“This synergy depends on cross-presentation of tumor-associated antigens to cytotoxic T cells by DCs in tumor-draining lymph nodes (Uribe-Herranz et al. 2020), indicating that the underlying mechanism depends on the immunomodulatory effects of SCFAs.”
BackgroundInfluence of Microbiota on Tumor Immunotherapy
Yu, X., Li, W., Li, Z., Wu, Q., & Sun, S. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.91771 · Cited by 37
“Tumor irradiation has been proven to be significantly boosted in the presence of vancomycin, which eradicates the immunosuppressive metabolites, especially butyrate and propionate, originating from Clostridia [185,195].”
BackgroundInfluentialCommensal microbe regulation of skin cells in disease
Gan, Y., Zhang, J., Qi, F., Hu, Z., Sweren, E., Reddy, S., Chen, L., Feng, X., Grice, E. A., Garza, L. A., et al. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.07.020 · Cited by 34
Dong, J., Gao, H.-L., Wang, W., Yu, X., & Liu, L. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188484 · Cited by 31
The Link Between the Microbiota and HER2+ Breast Cancer: The New Challenge of Precision Medicine
Modica, M. D., Arlotta, V., Sfondrini, L., Tagliabue, E., & Triulzi, T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.947188 · Cited by 36
“In particular, the depletion of vancomycin-sensitive bacteria enhances DC antigen presentation, improving the antitumor activity of RT (74).”
BackgroundInfluentialAl-Qadami, G. H., Bowen, J. M., Sebille, Y. Z. A. V., Secombe, K. R., Dorraki, M., Verjans, J. W. H., Wardill, H. R., & Le, H. V. (2023) · Supportive Care in Cancer · doi:10.1007/s00520-022-07559-5 · Cited by 38
Bifidobacterium affects antitumor efficacy of oncolytic adenovirus in a mouse model of melanoma
Tripodi, L., Feola, S., Granata, I., Whalley, T., Passariello, M., Capasso, C., Coluccino, L., Vitale, M., Scalia, G., Gentile, L., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107668 · Cited by 31
“Vancomycin treatment however reduced tumor growth compared to mock-treated mice: this observation is consistent with the current literature.(29) To assess how vancomycin pre-treatment influences the immune response induced by Ad-CpG, we analyzed the phenotype of tumor-infiltrating lymphocytes (TILs) in treated mice an…”
The role of microbiomes in gastrointestinal cancers: new insights
Yarahmadi, A., & Afkhami, H. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2023.1344328 · Cited by 30
Disentangling the molecular mystery of tumour–microbiota interactions: Microbial metabolites
Duan, Y.-W., Dai, J.-H., Lu, Y.-Q., Qiao, H., & Liu, N. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.70093 · Cited by 31
Role of Biological Sex in the Cardiovascular-Gut Microbiome Axis
Li, S., & Kararigas, G. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.759735 · Cited by 29
Brevi, A., Cogrossi, L. L., Lorenzoni, M., Mattorre, B., & Bellone, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.845422 · Cited by 32
Qiu, B., Yu, X., Liu, F., Li, Y., Xie, X., Guo, J., Guo, S., Wu, Y., Wu, L., Liang, T., et al. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2022.07.032 · Cited by 34
Combined use of NK cells and radiotherapy in the treatment of solid tumors
Wang, Z., Ling, S., Cao, Y., Shao, C., & Sun, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1306534 · Cited by 33
Metadata
- Authors
- Uribe-Herranz, M., Rafail, S., Beghi, S., Gil-de-Gómez, L., Verginadis, I., Bittinger, K., Pustylnikov, S., Pierini, S., Perales-Linares, R., Blair, I. A., Mesaros, C. A., Snyder, N. W., Bushman, F., Koumenis, C., & Facciabene, A.
- Affiliations
- University of Pennsylvania (US)
- Children's Hospital of Philadelphia (US)
- Drexel University (US)
- Corresponding author
- Koumenis, Constantinos
- Facciabene, Andrea
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2019-12-09
- Volume
- 130
- Issue
- 1
- Pages
- 466-479
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC6934221
- OpenAlex
- W2993330612
- Cited by
- 316
- References
- 79
- Citations by year
- 2026: 37 · 2025: 59 · 2024: 60 · 2023: 52 · 2022: 44 · 2021: 43 · 2020: 21
- FWCI
- 8.94
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Children's Hospital of Philadelphia
- University of Pennsylvania
- National Institutes of Health
- National Cancer Institute (R01CA116779, R01CA219871)
- National Institute of General Medical Sciences (R01GM132261)
- National Institute of Environmental Health Sciences (P30ES013508)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- gut microbiota, radiotherapy, dendritic cells, antigen presentation, antitumor immunity, vancomycin, butyrate, CD8+ T cells, interferon-gamma, abscopal effect
- MeSH terms
- Gastrointestinal Microbiome, Animals, Antigens, Neoplasm, Butyrates, Dendritic Cells, Female, Neoplasms, Experimental, Antigen Presentation, Mice, Knockout, CD8-Positive T-Lymphocytes, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.